The Sprint-A satellite with the EUV spectrometer (Extreme Ultraviolet Spectroscope for Exospheric Dynamics: EXCEED) was launched in September 2013 by the Epsilon rocket. Now it is orbiting around the Earth (954.05 km × 1156.87 km orbit; the period is 104 minutes) and one has started a broad and varied observation program. With an effective area of more than 1 cm 2 and well-calibrated sensitivity in space, the EUV spectrometer will produce spectral images (520-1480 Å) of the atmospheres/magnetospheres of several planets (Mercury, Venus, Mars, Jupiter, and Saturn) from the Earth's orbit. At the first day of the observation, EUV emissions from the Io plasma torus (mainly sulfur ions) and aurora (H 2 Lyman and Werner bands) of Jupiter have been identified. Continuous 3-month measurement for Io's plasma torus and aurora is planned to witness the sporadic and sudden brightening events occurring on one or both regions. For Venus, the Fourth Positive (A 1 Π -X 1 Σ + ) system of CO and some yet known emissions of the atmosphere were identified even though the exposure was short (8-min). Long-term exposure from April to June (for approximately 2 months) will visualize the Venusian ionosphere and tail in the EUV spectral range. Saturn and Mars are the next targets.

gp130 is a common signal-transducing receptor subunit for the interleukin (IL)-6 cytokine family. Studies in genetically engineered animal models have demonstrated a critical role for the gp130-dependent cardiomyocyte survival pathway in the transition to heart failure. In the present study, we examined plasma levels of the IL-6 family of cytokines and the soluble form of their receptors in patients with congestive heart failure (CHF). Circulating levels of the IL-6 family of cytokines, soluble IL-6 receptor (sIL-6R), and soluble gp130 (sgp130) were examined in 48 patients with various degrees of CHF, including dilated cardiomyopathy (DCM), ischemic cardiomyopathy (ICM), and valvular cardiomyopathy (VCM). Circulating levels of IL-6, leukemia inhibitory factor (LIF), and sgp130 significantly increased in association with the severity of CHF. No significant difference was observed in the circulating levels of sIL-6R and IL-11 among these patients. Interestingly, DCM patients showed higher circulating sgp130 levels than patients with ICM or VCM. Our findings suggest that gp130 expression in the heart is likely to be dynamic, and that the IL-6 family of cytokines and their common receptor gp130 participates in the pathogenesis of CHF, especially in DCM.

High‐performance liquid chromatographic (HPLC) analysis of human serum albumin (HSA) on Asahipak GS‐520 showed at least two peaks, the principal component corresponding to human mercaptalbumin (HMA) and the secondary one to nonmercaptalbumin (HNA). HPLC analysis of HSA on Asahipak ES‐520 N showed three peaks, the principal component corresponding to HMA, the secondary one to HNA having mixed disulfide with cysteine or glutathione and the tertiary one to HNA oxidized higher than mixed disulfide. Two kinds of rapid HPLC for the resolution of HSA into HMA and HNA were developed by the present authors. Using these HPLC, the present authors found a significant decrease in the fraction of HMA in the elderly.

No abstract